Tag: M.W:200-300

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

COMPOUND 6; 5-[3,5-bis-(3-Trimethyla?imoiiio-prop3doxy)-phenyl3-15-undecyl- porphyrin dichloride; To a vigorously-stirred suspension of Compound 5 (80 mg, 0.14 mmol) and K2CO3 (230 mg, 1.7 mmol) in DMF (30 mL) is added (1- bromopropyl)-trimethylammomum bromide (0.3 g, 16.6 mmol) at 50 0C. The mixture is stirred at this temperature for 18 h. After removal of the DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. IL) the crude product is eluted with acetic acidrmethanol .-water (3:2:1, by vol.). Appropriate fractions are collected and, after evaporation of the solvent under reduced pressure, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (5:4:1, by vol., upper phase). After removal of the solvent from appropriate fractions under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After collection of the eluate, solvent is removed under reduced pressure and the residue obtained is dried under high vacuum to yield the dichloride salt as a violet solid.1H-NMR: deltaH (300Mz, CD3OD): 0.75 (t, 3J l.5 Hz, 3 H), 1.05-1.20 (m, 14 H), 1.45- 1.50 (m, 2 H), 2.05-2.15 (m, 4 H), 2.15-2.20 (m, 2 H)5 2.95 (s, 18 H), 3.35-3.45 (m, 4 H), 3.95 (t, 3J 7.5 Hz, 4 H), 4.55 (t, 3J 7.5 Hz, 2 H), 6.85 (m, 1 H)5 7.35 (m, 2 H), 8.85-8.90, 9.15-9.20, (3 x m, 8 H), 10.10 (s, 2 H)., 3779-42-8

As the paragraph descriping shows that 3779-42-8 is playing an increasingly important role.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

Compound 14 (50 mg, 0.05 mmol) is dissolved and K2C03 (150 mg, 1.1 mmol) is suspended in DMF (30 mL). To the vigorously-stirred mixture a solution of (1-BROMOPROPYL)-TRIMETHYLAMMONIUM bromide (0.3 g, 16.6 mmol) in DMF (10 mL) is added dropwise at 50C and the mixture is heated for 18 h. After removal of DMF under high vacuum, the residue obtained is dissolved in methanol (5 ML) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 CM). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid: methanol: water (3: 2: 1, by vol. ). After evaporation of solvent from appropriate combined fractions the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (5: 4: 1, by vol. , upper phase) for further separation from the excess ammonium salt and other by-products. After removal of solvent under reduced pressure the residue obtained is dissolved in methanol and passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After evaporation of solvent under reduced pressure, the product is dried under high vacuum. 1 H-NMR : sH (300MHZ, CD30D): 0.80 (t, 3J 7.5 Hz, 6 H), 1.15-1. 35 (m, 28 H), 1.35-1. 45 (bs, 4 H), 1.70-1. 80 (bs, 4 H), 2.30-2. 40 (BS, 4 H), 3.15-3. 30 (bs, 18 H), 3.65-3. 75 (bs, 4 H), 4.00-4. 05 (m, 4 H), 4.30-4. 40 (bs, 4 H), 7.00-7. 15,7. 20-7.30, 7. 80-95, 7.95-8. 15 (4 x m, 4 x 4 H), 8.60-9. 00 (bs, 8 H)., 3779-42-8

3779-42-8 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide 151145, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.

Resolution of the enantiomers of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid The resolution of the enantiomers of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid was carried out via reaction with the following chiral bases: BrucineQuinine(-)-Cinchonidine(+)-CinchonineR-(+)-1-Phenylethylamine(1 R,2S)-(-)-Ephedrine hydrochloride(1S,2R)-(+)-Ephedrine hydrochloride. In each case the reactions were carried out with 0.5 and 1 equivalents of base in respect to 1 equivalent of the acid compound and by using the following solvents EthanolAcetoneAcetonitrilDioxaneEthylacetateChloroform. The results are summarized in the following tables. It may be understood that the afore mentioned crystallisation experiments that are not reflected in the following tables did not yield crystals of the respective salts under the given conditions. However, suitable conditions for crystallization of these salts can be determined by those skilled in the art via routine experiments. In the following tables Acid represents racemic 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazo)e-3-carboxylic acid R-Acid represents the respective derivative of (R)-5-( 4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid S-Acid represents the respective derivative of (S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acidProcesses for crystallisation: Process A: A solution of the chiral base was added on top of a solution of the racemic acid at room temperature.Process C: A solution of the racemic acid was added on top of a solution of the chiral base. The mixture was heated to reflux and solvent was added until dissolution was complete. The solution was left to crystallisation at r.t.Process D: The chiral base was directly added on top of a solution of the racemic acid at room temperature.Process E: The chiral base was directly added on top of a solution of the racemic acid at reflux temperature.Process F: The solution of the salt was evaporated to dryness. The residue was dissolved in a minimum amount of the solvent under reflux heating. The solution was left to crystallisation at r.t.Resolution with (-)-Cinchonidine [Show Image] Acid g (mmol) Eq. amine Proc. Solvent for crystallisation T CrystYield 1st Cryst. % % S-Acid % R-Acid0,4 g (1,09 mmol) 1 F 2ml dioxane r.t 31 94,4 5,60,4 g (1,09 mmol) 1 F 19ml Ethylacetate r.t 28,5 95,8 4,20,4 g (1,09 mmol) 1 F 20ml acetone r.t. 19,6 96,9 3,10,4 g (1,09 mmol) 1 F 24ml acetonitrile r.t 42 85,8 14,1

As the paragraph descriping shows that 485-71-2 is playing an increasingly important role.

Reference£º
Patent; Laboratorios del Dr. Esteve S.A.; EP1944293; (2008); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787-70-2,[1,1′-Biphenyl]-4,4′-dicarboxylic acid,as a common compound, the synthetic route is as follows.,787-70-2

In a typical preparation, a solid mixture of H2BPDC (H2BPDC = 4,4′-biphenyldicarboxylic acid; 0.1039 g, 0.4 mmol), BPY (BPY = 4,4′-bipyridine; 0.033 g, 0.2 mmol), and Cu(NO3)2.3H2O (0.105 g, 0.4 mmol) was dissolved in a mixture of DMF (DMF = N,N’-dimethylformamide; 30 mL), pyridine (0.3 mL), and methanol (3 mL). The resulting solution was stirred at 70 C for 5 min, and then distributed to four 20 mL vials. The vials were then heated at 120 C in an isothermal oven for 24 h. After cooling the vials to room temperature, the solid product was removed by decanting with mother liquor and washed in DMF (3 * 10 mL) for 3 days. Solvent exchange was carried out with methanol (3 * 10 mL) at room temperature for 3 days. The material was then evacuated under vacuum at 140 C for 6 h, yielding 0.103 g of Cu2(BPDC)2(BPY) in the form of blue crystals (67.5% based on copper nitrate).

The synthetic route of 787-70-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Le, Hanh T.N.; Nguyen, Tung T.; Vu, Phuong H.L.; Truong, Thanh; Phan, Nam T.S.; Journal of Molecular Catalysis A: Chemical; vol. 391; 1; (2014); p. 74 – 82;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

99970-84-0, [2,2′-Bipyridine]-4,4′-dicarbaldehyde is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

99970-84-0, Dry potassium carbonate (1.7 g, 12.3 mmol) and 2.1 gtriethylphosphonoacetate were suspended in 10 cm3 of anhydrousTHF and stirred at room temperature for 15 min beforethe suspension was refluxed for 20 min. After cooling thesuspension to room temperature it was transferred into amicrowave vessel and 1.0 g (4.7 mmol) of (7) in 2 cm3 anhydrousTHF were added. The vessel was sealed and heated to110 C within 10 min using a maximum power of 1000MW.The reaction temperature then was maintained for 2 h afterwhich the vessel was allowed to cool down to room temperature.After cooling, 20 cm3 of a 10% potassium carbonatesolution was added. The mixture was extracted three timeswith ethyl acetate. The organic phase was dried over sodiumsulfate and the solvent was evaporated under reduced pressure.The remaining triethylphosphonoacetate was removedby distillation in vacuo. The crude product was purified bycolumn chromatography on silica gel using a diethyl ether:light petroleum (40-60) 1 : 1 mixture as the eluent. After thesolvent mixture was evaporated a white solid was obtainedwhich was recrystallized from ethanol/water by first dissolvingthe crude product in ethanol and then adding wateruntil the solution misted. For complete crystallization thesolution was placed in the refrigerator. Yield: 40% (0.66 g,1.88 mmol).IR (298 K) [cm-1]: 2980w, 2936vw, 1726vs, 1697vs,1584m, 1545w, 1458m, 1443m, 1377s, 1294s, 1263s, 1217vs,1063vs, 1011s, 991m, 930w, 880w, 860w, 843m, 791s, 770w,746m; MS (EI) m/z (%): 352 (10) [M+]; 323 (5) [M+-C2H5]; 308 (70) [M+-C2H5 – CH3]; 280 (100) [M+-C4H9O];261 (20) [M+-C4H11O2]; 233 (25) [M+-C6H15O2]; 208 (70)[M+-C8H18O2]; 1HNMR(CDCl3):delta ppm 1.36 (t, J = 7.07Hz, 6 H) 4.30 (q, J = 7.16 Hz, 4 H) 6.73 (s, 1 H) 6.77 (s, 1H) 7.41 (dd, J = 5.05, 1.77 Hz, 2 H) 7.73 (s, 1 H) 7.69 (s, 1H) 8.55-8.58 (m, 2 H) 8.73 (d, J = 5.05 Hz, 2 H); 13C-NMR(CDCl3):delta [ppm] = 14.2, 61.0, 119.3, 122.2, 123.1, 141.8,142.8, 150.0, 156.4, 166.1; M.p.: 139 C; elemental analysis:calc. (%) for C20H20N2O4: C 68.17, H 5.72, N 7.95; found:C 67.30, H 5.66, N 8.03.

As the paragraph descriping shows that 99970-84-0 is playing an increasingly important role.

Reference£º
Article; Heintz, Katharina; Goerls, Helmar; Imhof, Wolfgang; Journal of Chemical Sciences; vol. 130; 6; (2018);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

78902-09-7,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.78902-09-7,2-(2,2-Diethoxyethyl)isoindoline-1,3-dione,as a common compound, the synthetic route is as follows.

2-{2-ethoxy-2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]ethyl}-1H-isoindole-1,3(2H)-dione (Compound 42) To 50 ml dichloromethane solution of 2-(2,2-diethoxyethyl)-1H-isoindole-1,3(2H)-dione (6.8 g, 25.8 mmol) under an ice bath was added 2,6-lutidine (9.89 mL, 85 mmol) and TMSOTf (10.3 mL, 56.8 mmol). The reaction stirred under the ice bath for one hour. After which, (9Z,12Z)-octadeca-9,12-dien-1-ol (24.3 mL, 77 mmol) was added in and the reaction was stirred from 0 C. to 20 C. for 16 hours. The reaction was diluted with 200 mL dichloromethane and washed by 100 mL of NaHCO3 solution, water, brine. The organic was dried over Na2SO4, filtrated and purified by silica gel chromatography (0% ethyl acetate/hexane?18% ethyl acetate/hexane) to give title compound (12.1 g). MS 506.5 (M+Na).

The synthetic route of 78902-09-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SIRNA THERAPEUTICS, INC.; Colletti, Steven L.; Deng, Zhengwu James; Stanton, Matthew G.; Wang, Weimin; Hills, Ivory; (47 pag.)US9670487; (2017); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29841-69-8, (1S,2S)-(-)-1,2-Diphenylethylenediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Bis-aldehyde c (0.53 g,1.1 mmol) in dry THF (1.2 mL) was taken in a single-necked 50 mL round-bottom flask to which the solution of 1S,2S-(+)-1,2-diaminocyclohexane (0.14 g,1.2 mmol)/1S,2S-(-)-1,2-diphenylethane-1,2-diamine (0.27 g, 1.2 mmol) in dry THF (0.6 mL) was added slowly and the resultant solutions were stirred at room temperature. After completion of the reaction (2 h) checked on TLC, the solvent was removed completely under reduced pressure. The bright yellow solids were extracted with dichloromethane (50 mL), and the organic layer was washed with water (3 ¡Á 50 mL), brine (3 ¡Á 50 mL) and finally dried over anhydrous Na2SO4. After removal of dichloromethane under reduced pressure, the chiral dimeric macrocyclic ligands 3′ and 4′ were purified by silica gel chromatography (100-200 mesh) with a EtOAc-to-Hexane of 3:2.3′: Yield 96%. m.p. 76 C. 1H NMR (500 MHz, CDCl3): delta 1.38 (36H, s),1.67-1.93 (16H, m), 3.32 (4H, m), 3.55 (8H, t, J = 5), 3.61 (16H, t, J = 7), 4.37 (8H, s), 6.97 (4H, s), 7.20 (4H, s), 8.26 (4H, s), 13.86 (4H, br) ppm. 13C NMR (125 MHz, CDCl3): 25.0, 31.0, 34.7, 70.7, 72.2, 74.0, 74.8, 79.0, 119.8, 128.7, 131.2, 138.8, 161.6, 167.0 ppm; FT-IR (KBr): nu 3424, 2934, 2863, 2361, 1628, 1537, 1446, 1384, 1317, 1239, 1098, 940, 868, 785, 671, 563, 420 cm-1. (c = 0.052, CH2Cl2). Anal. Calcd. for C72H104N4O12 C, 71.02; H, 8.61; N, 4.60. Found C, 71.05; H, 8.63; N, 4.62. MALDI-TOF: m/z Calcd. for [C72H104N4O12] 1217.62, Found 1218.19 [M+H].4′: Yield 93%. m.p. 95 C. 1H NMR (200 MHz, CDCl3): delta 1.40 (36H, s), 3.53-3.63 (24H, m), 4.37 (8H, s), 4.71 (4H, s), 6.97 (4H, s), 7.19-7.29 (24H, m), 8.32 (4H, s), 13.78 (4H, br) ppm. 13C NMR (50 MHz, CDCl3): 29.3, 34.8, 69.1, 70.6, 73.1, 80.0, 118.1, 127.6, 128.1, 128.3, 129.8, 137.3, 139.5, 159.9, 166.7 ppm. FT-IR (KBr): nu 3452, 2952, 2865, 2361, 1626, 1446, 1386, 1357, 1320, 1266, 1208, 1100, 1035, 936, 871, 801, 775, 573 cm-1. (c = 0.108, CHCl3). Anal. Calcd. for C88H108N4O12 C, 74.76; H, 7.70; N, 3.96. Found C, 74.75; H, 7.73; N, 3.98. MALDI-TOF: m/z Calcd. for [C88H108N4O12] 1413.82, Found 1414.19 [M+H].

29841-69-8, The synthetic route of 29841-69-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Kureshy, Rukhsana I.; Roy, Tamal; Khan, Noor-Ul H.; Abdi, Sayed H.R.; Sadhukhan, Arghya; Bajaj, Hari C.; Journal of Catalysis; vol. 286; (2012); p. 41 – 50;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.29841-69-8,(1S,2S)-(-)-1,2-Diphenylethylenediamine,as a common compound, the synthetic route is as follows.

To a solution of (S,S)-1,2-diphenylethane-1,2-diamine (424 mg,2 mmol) and triethylamine (280 muL, 2 mmol) in CH2Cl2 (10 mL), 4-(bromomethyl)phenylsulfonyl chloride 1 (525 mg, 1.96 mmol) in dichloromethane(10 mL) were added dropwise at 0 C. The reactionmixture was stirred at room temperature for 0.5 h. After removal ofsolvents under reduced pressure, the residue was purified by silica gelcolumn chromatography. The product 3 was obtained as white solid(0.45 g, 60%). 1H NMR (400 MHz, CDCl3) delta 7.46-7.31 (m, 2H),7.27-6.98 (m, 12H), 4.50 (s, 2H), 4.45 (d, J=5.1 Hz, 1H), 4.20 (d,J=5.2 Hz, 1H). 13C NMR (100 MHz, CDCl3) delta 141.5, 140.0, 136.9,129.0, 128.6, 128.3, 128.2, 127.7, 127.5, 127.5, 127.4, 63.0, 60.0,31.7. HRMS (ESI): m/z calculated for C21H21N2O2SBr [M+H]+:445.0580; found: 445.0583., 29841-69-8

29841-69-8 (1S,2S)-(-)-1,2-Diphenylethylenediamine 6931238, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Zheng, Dongsong; Liu, Rui; Wang, Yu; Cheng, Tanyu; Liu, Guohua; Molecular catalysis; vol. 455; (2018); p. 103 – 107;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

Example: Zetaeta(NuO3) 2 ¡¤ 6H20 (29.7 mg, 0.1 mmol), 2,2′-biquinoline (25.6 mg, 0.1 mmol), 2,2 -biphenyl diacid (24.0 mg, 0.1 mmol) and NaN3 (13.2 mg, 0.2 mmol), were added to a mixed solvent of 12 mL methanol and secondary deionized water (1:1 volume ratio), It was sealed in a 25 mL stainless steel container lined with tetrafluoroethylene, heated to 140 C for 3 days, and then slowly cooled to room temperature. After filtration, the filter cake was washed with diethyl ether and dried in air to obtain colorless massive crystals, the calculated yield based on Zn(N03)2¡¤6H20 was approximately 61%. This material was insoluble in water and other organic solvents.

119-91-5, As the paragraph descriping shows that 119-91-5 is playing an increasingly important role.

Reference£º
Patent; Anqing Teachers College; Xu Heng; Yan Da; Feng Xuejun; Chen Zhengxiang; Xiong Zhi; Huang Rongyi; (9 pag.)CN108017661; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29841-69-8, (1S,2S)-(-)-1,2-Diphenylethylenediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

0.592 g (2.79 mmol) of (S,S)-DPEN (MW: 212.3) was introduced into a 50-mL three-necked flask and subjected to argon-gas replacement. 25 mL of dehydrated methylene chloride and 0.41 mL (2.93 mmol) of triethylamine were added and cooled to 0 C. To this solution, a solution consisting of 0.515 g (2.79 mmol) of isohexyl sulfonyl chloride (MW: 184.68) and 25 mL of dehydrated methylene chloride was slowly added dropwise, and stirred at 0 C. for one night. This solution was washed twice with water, then the solvent in the organic layer was distilled away, and dried under reduced pressure to give 1.656 g of a crude product. The crude product was purified by silica-gel column chromatography (silica gel 60N, n-hexane:AcOEt=1:1, then AcOEt 100%) to give 0.306 g of (S,S)-(C2H5)2CHCH2SO2DPEN (30% yield). 1H NMR (400 MHz, CDCl3, rt, delta/ppm): 0.67 (q, J=7.3 Hz, 6H, (C3CH2)2CH), 1.10-1.38 (m, 4H, (CH3C2)2CH), 1.62-1.76 (m, 1H, (CH3CH2)2C), 2.22 (d, J=6.4 Hz, 2H, C2SO2), 4.29 (d, J=5.5 Hz, 1H, C6H5CNH2), 4.56 (d, J=5.5 Hz, 1H, C6H5CNHSO2), 7.15-7.45 (m, 10H, aromatic proton).

29841-69-8, 29841-69-8 (1S,2S)-(-)-1,2-Diphenylethylenediamine 6931238, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Kanto Kagaku Kabushiki Kaisha; US2010/261924; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI